^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JANX008
i
Other names: JANX008, EGFR-TRACTr
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Janux Therapeutics
Drug class:
EGFR inhibitor, T-cell stimulant, CD3 modulator
Related drugs:
1year
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=130, Recruiting, Janux Therapeutics | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
JANX008
1year
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=130, Not yet recruiting, Janux Therapeutics
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
JANX008
over1year
Preclinical Activity and Safety Profile or JANX008, a Novel EGFR-Targeting Tumor-Activated T Cell Engager for Treatment of Solid Tumors (SITC 2022)
Finally, the cleavable albumin-binding domain extended the half-life of JANX008 to ~94h, relative to the ~1.3h half-life of non-masked TCE, supporting its weekly clinical dosing. Conclusions Preclinical data demonstrate key characteristics of JANX008, including cleavage-dependent activity, half-life extended PK, the potential for superior safety, and manufacturability properties that could mitigate significant limitations of TCEs and support JANX008 clinical development.
Preclinical
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • EGFR expression
|
JANX008
Share via
